Aventus Health adds highly reliable COVID-19 variant test to its suite of COVID-19 tests and services to accurately identify known and novel variants.
ORLANDO, Fla.–(BUSINESS WIRE)–Today, Aventus Health (Aventus), a comprehensive healthcare company focused on making precision medicine accessible and affordable, announced the availability of their COVID-19 Variant Test, created to reliably identify known SARS-CoV-2 variants and the discovery of novel variants. Aventus’ COVID-19 Variant Test was developed through an innovative application of its Next-Generation Sequencing (NGS) technology and the cutting-edge, laboratory-developed assay that together break down the sequence of base pairs that constitute the genetic makeup of the various strains of corona virus. The result is a reliable test result that can advance the study, tracking and understanding of emerging COVID-19 variants and their potential impact on public health.
Aventus offers a suite of COVID-19 testing services and will now include reflex testing-to-NGS on all Aventus’ RT-PCR patient tests that return a positive result in order to identify currently known variants as well as those yet to be discovered. There is no additional cost or special instructions for individuals using Aventus’ tests.
“Aventus Health has been at the forefront of responding to COVID-19,” noted Oliver Dawoud, Aventus CEO. “Our world-class laboratory scientists and technicians are renowned for their innovations in genomics and diagnostics. At the onset of the pandemic, Aventus released one of the most accurate COVID-19 RT-PCR tests in the market and went on to make COVID-19 testing widely available through our partnerships. To complete our wide array of services, we were able to utilize our state-of-the-art technology to bring to market SARS-CoV-2 variant testing. This is a breakthrough in healthcare that will greatly aid the general public in better understanding the different strains of COVID-19. It will allow us to know what strain an individual has and even get ahead of the curve on any new strains that may develop.”
Aventus’ Medical Director, Michelle Taylor, MD explains that variant testing is complicated and not widely available because it requires scientists use a process called genomic sequencing, which requires advanced and expensive technology and diagnostic expertise. “The instruments Aventus uses are manufactured for the highest sensitivity genetic sequencing capabilities on the market,” Dr. Taylor noted. “They are critical to our mission of helping healthcare providers leverage innovations in genomics and diagnostics to deliver affordable and effective personalized and precision medicine. Addressing the need for COVID-19 and variant testing and diagnostics is a natural fit for us.”
ABOUT AVENTUS HEALTH
Aventus Health is a comprehensive healthcare leader that is transforming the industry by making personalized and precision medicine accessible and affordable to providers and patients. Aventus Health is comprised of a diverse portfolio of integrated healthcare service companies and clinical care facilities to provide a seamless platform for a wide range of cost-effective and advanced solutions – from diverse laboratory diagnostics with predictive and prescriptive analytics to specialized pharmacies and interventional specialists. www.aventushealth.com
CZG Strategic Communications